MONISTAT 7 COMBINATION PACK

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MONISTAT 7 COMBINATION PACK (MONISTAT 7 COMBINATION PACK).

How it works

Miconazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, preventing conversion of lanosterol to ergosterol, thereby disrupting fungal cell membrane synthesis.

What the body does with it

Metabolism	Minimal systemic absorption; primarily metabolized in the liver via oxidative pathways.
Excretion	Miconazole is primarily metabolized in the liver; less than 1% of absorbed dose is excreted unchanged in urine. Fecal excretion accounts for approximately 50% of the dose, primarily as metabolites. Biliary excretion is minimal.
Half-life	Terminal elimination half-life is approximately 24 hours for miconazole after systemic absorption, reflecting slow tissue redistribution and hepatic clearance. After intravaginal administration, systemic absorption is minimal (<1.4%), so half-life is not clinically relevant.
Protein binding	Miconazole is 90–93% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Apparent volume of distribution (Vd) is approximately 20–30 L/kg, indicating extensive tissue penetration and distribution into peripheral compartments such as skin and mucous membranes.
Bioavailability	Intravaginal: Systemic bioavailability is <1.4% after vaginal administration. Oral: Not formulated for systemic use; oral bioavailability is low (<25%) due to extensive first-pass metabolism.
Onset of Action	Intravaginal: Symptom relief (itching, burning) begins within 24–48 hours after application. Complete resolution of infection typically requires 7 days.
Duration of Action	Intravaginal: Suppository provides sustained release over 24 hours; clinical effects persist for the treatment duration of 7 days. The cream provides rapid relief but is reapplied daily.

Classification & Brands

Dosing & administration

Intravaginal: one applicatorful (200 mg miconazole nitrate) at bedtime for 7 nights. Also: topical cream (2%) applied to affected area twice daily for 7 days.

Dosage form	CREAM, SUPPOSITORY
Renal impairment	No dose adjustment required for renal impairment.
Liver impairment	No dose adjustment required for Child-Pugh A or B. For Child-Pugh C, use with caution due to limited data.
Pediatric use	Children ≥12 years: same as adult. Children <12 years: safety not established; use only under medical supervision.
Geriatric use	No specific dose adjustment; same as adult dosing. Monitor for local irritation.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MONISTAT 7 COMBINATION PACK (MONISTAT 7 COMBINATION PACK).

Breastfeeding	Miconazole is excreted into breast milk in very small amounts (<1% of maternal dose) due to low systemic absorption after vaginal administration. M/P ratio not determined. Considered compatible with breastfeeding; avoid direct application to nipple or areola.
Teratogenic Risk	FDA Pregnancy Category C (pre-2015). Miconazole use in first trimester has been associated with a small increased risk of spontaneous abortion in some observational studies, but no consistent evidence of major congenital malformations. Vaginal absorption is minimal (1-2%); systemic exposure is low. Risk appears minimal, but use only if clearly needed, especially in first trimester.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to any component","Known history of hypersensitivity to imidazole antifungals"]

Clinical Precautions

Precautions

["For intravaginal use only","Do not use if abdominal pain, fever, or foul-smelling discharge present","Discontinue if irritation or sensitization occurs","Do not use during menstruation","If no improvement within 3 days, re-evaluate diagnosis"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

MONISTAT 7 COMBINATION PACK

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MONISTAT 7 COMBINATION PACK (MONISTAT 7 COMBINATION PACK).

How it works

Miconazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, preventing conversion of lanosterol to ergosterol, thereby disrupting fungal cell membrane synthesis.

What the body does with it

Metabolism	Minimal systemic absorption; primarily metabolized in the liver via oxidative pathways.
Excretion	Miconazole is primarily metabolized in the liver; less than 1% of absorbed dose is excreted unchanged in urine. Fecal excretion accounts for approximately 50% of the dose, primarily as metabolites. Biliary excretion is minimal.
Half-life	Terminal elimination half-life is approximately 24 hours for miconazole after systemic absorption, reflecting slow tissue redistribution and hepatic clearance. After intravaginal administration, systemic absorption is minimal (<1.4%), so half-life is not clinically relevant.
Protein binding	Miconazole is 90–93% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Apparent volume of distribution (Vd) is approximately 20–30 L/kg, indicating extensive tissue penetration and distribution into peripheral compartments such as skin and mucous membranes.
Bioavailability	Intravaginal: Systemic bioavailability is <1.4% after vaginal administration. Oral: Not formulated for systemic use; oral bioavailability is low (<25%) due to extensive first-pass metabolism.
Onset of Action	Intravaginal: Symptom relief (itching, burning) begins within 24–48 hours after application. Complete resolution of infection typically requires 7 days.
Duration of Action	Intravaginal: Suppository provides sustained release over 24 hours; clinical effects persist for the treatment duration of 7 days. The cream provides rapid relief but is reapplied daily.

Classification & Brands

Dosing & administration

Intravaginal: one applicatorful (200 mg miconazole nitrate) at bedtime for 7 nights. Also: topical cream (2%) applied to affected area twice daily for 7 days.

Dosage form	CREAM, SUPPOSITORY
Renal impairment	No dose adjustment required for renal impairment.
Liver impairment	No dose adjustment required for Child-Pugh A or B. For Child-Pugh C, use with caution due to limited data.
Pediatric use	Children ≥12 years: same as adult. Children <12 years: safety not established; use only under medical supervision.
Geriatric use	No specific dose adjustment; same as adult dosing. Monitor for local irritation.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MONISTAT 7 COMBINATION PACK (MONISTAT 7 COMBINATION PACK).

Breastfeeding	Miconazole is excreted into breast milk in very small amounts (<1% of maternal dose) due to low systemic absorption after vaginal administration. M/P ratio not determined. Considered compatible with breastfeeding; avoid direct application to nipple or areola.
Teratogenic Risk	FDA Pregnancy Category C (pre-2015). Miconazole use in first trimester has been associated with a small increased risk of spontaneous abortion in some observational studies, but no consistent evidence of major congenital malformations. Vaginal absorption is minimal (1-2%); systemic exposure is low. Risk appears minimal, but use only if clearly needed, especially in first trimester.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to any component","Known history of hypersensitivity to imidazole antifungals"]